Table 3.
The replacement to silent mutation ratios and homologies with germline genes of the light chains for the 15 anti-DNA Fabs. Figures in italics are those for which there are no silent mutations
| VL | Jκ | Combined R/S ratio for CDRs 1, 2 and 3 | R/S ratio for CDR1 | R/S ratio CRD2 | R/S ratio CRD3 | R/S ratio in the framework region | Transition mutation rate |
|---|---|---|---|---|---|---|---|
| A27(1)1 | Jκ1 | 2 | 1 | 0 | 3 | 0·5 | 27·3 |
| A27(2)2 | Jκ1 | 3 | 0 | 2 | 1 | 2 | 81·8 |
| A20 | Jκ4 | 2·75 | 3 | 2 | 2 | 1·7 | 50·0 |
| B3(1)3 | Jκ4 | 3·5 | 3 | 0 | 3·67 | 3·8 | 41·0 |
| B3(2)4 | Jκ4 | 4 | 2 | 0 | 2 | 4·0 | 47·1 |
| Mean | 3·05 | 1·8 | 0·8* | 2·33 | 2·4 | 49·4 |
*
Probability value, P > 0·005 when compared with total ratio of the CDRs and> 0·03 when compared with the CDR3, but not significant when compared with the CDR1·
1
Somatic variant of A27/Jκ1 light chain used by antibodies R4C07, R4C09, R4C12, R4C15 and R5C02.
2
Somatic variant of A27/Jκ1 light chain used by antibodies R4C04, R4C17 and R5C06.
3
Somatic variant of B3/Jκ4 light chain used by antibody P212.
4
Somatic variant of B3/Jκ4 light chain used by antibody P253. The sequence differences between these light chains are described in Fig. 2.